Introduction
Hyaluronan, or hyaluronic acid (HA), is an unsulfated long polysaccharide chain comprised of repeating disaccharide units of N-acetylglucosamine and glucuronic acid, and a major component of the extracellular matrix (ECM). HA is present with a high molecular mass in mammalian bone marrow and connective tissues, as well as skin, vitreous humor of the eye, cartilage, and umbilical cord tissue. Unlike other glycosaminoglycans, it is synthesized as a free polysaccharide, rather than substituted on a core protein, and newly synthesized HA polymers of 2,500e25,000 repeating disaccharides have a molecular mass ranging from 10 3 e10 4 kDa. The roles of HA range from purely structural functions to regulation of several cellular responses including proliferation, differentiation, motility, adhesion and gene expression. 1, 2 High molecular weight hyaluronic acid (HMW-HA) is clinically used as a symptom-or disease-modifying drug for non-surgical treatments of joints as well as cartilage diseases such as osteoarthritis (OA) 3 , as the efficacy of articular HA therapy for OA has been demonstrated in animal experimental models 4, 5 and clinical trials 6, 7 . Although the underlying mechanisms may be due to its chondroprotective and anti-inflammatory effects, the precise roles of HA in the pathogenesis of OA remain largely unknown.
Many connective tissue cells exhibit a large HA and proteoglycan-rich pericellular matrix that is tethered to the cell surface via interactions with the HA receptor CD44 8 , a multifunctional transmembrane glycoprotein that exhibits extensive molecular heterogeneity. The CD44 ectodomain is responsible for the binding of HA, while the cytoplasmic domain regulates specific signaling such as RhoA-activated Rho kinase 9 , Rho/Rac1-specific guanine nucleotide exchange factors (p115RhoGEF 10 , Tiam1 11 , and Vav2 12 ), c-Src kinase 13 , and transforming growth factor-b receptors 14 . CD44 also directly binds to cytoskeletal proteins such as ankyrin and ERM (ezrin, radixin, moesin). 15 Bone remodeling is a highly regulated process involving the coordinated action of osteoblasts and osteoclasts. Osteoclasts originate from hematopoietic precursors of a monocyte/macrophage lineage and differentiate into multinucleated giant cells specialized to resorb bone by fusion of mononuclear progenitors 16 .
It has also been shown that osteoclast precursors must interact with osteoblasts/stromal cells to differentiate into mature osteoclasts 17 , while osteoclast formation is induced in the presence of the receptor activator of the NF-kB ligand (RANKL), a member of the tumor necrosis factor (TNF) superfamily, which is expressed by osteoblasts/bone stromal cells. RANKL interacts with the osteoclast cell surface receptor RANK, which in turn recruits TNF receptorassociated factors (TRAFs) 18 , and plays a crucial role in the osteoclast differentiation axis. It is possible that receptor-mediated effects of HA and derivatives lead to changes in the metabolism of chondrocytes 19, 20 , synoviocytes 21, 22 , and subchondral bone osteoblasts 23 , and several researchers have reported the involvement of HA in osteoclast formation and resorption 24, 25 . In a previous study, we demonstrated that low molecular weight HA (LMW-HA, molecular weight <8 kDa) enhanced both osteoclast formation and function in vitro 26 . However, scant attention has been given to the effects of HMW-HA on osteoclast-supporting cells. In the present study, we examined the effects of HMW-HA on osteoclastogenesis and found that it suppressed osteoclast formation via down-regulation of RANKL in bone marrow derived osteoblastic/ stromal cells in vitro.
Methods

Reagents and antibodies
High molecular weight HA (HMW-HA, molecular weight 2,500 kDa) was supplied by Seikagaku Corp. (Tokyo, Japan), while 4-methylumberlliferone (4-MU) was purchased from Sigmae Aldrich (St. Louis, MO, USA). The anti-RANKL polyclonal antibody was obtained from R&D Systems Inc. 
Cell cultures
Mouse bone marrow stromal cells ST2 was obtained from Riken Cell Bank (Ibaraki, Japan) and maintained in alpha-minimum essential medium (a-MEM; GIBCO, Grand Island, NY, USA) supplemented with 10% fetal calf serum (FCS; SigmaeAldrich), 100 U/ ml penicillin G (Meiji Seika Pharm Co., Tokyo, Japan), and 100 mg/ml streptomycin (Wako Pure Chemical Industries, Osaka, Japan) at 37 C in an atmosphere of 5% CO 2 . ST2 cells were incubated with HMW-HA or 4-MU for various times. For some experiments, cells were pre-treated with the anti-CD44 monoclonal antibody (10 mg/ ml, Calbiochem, San Diego, CA, USA), simvastatin (10 mM, Sigmae Aldrich), or Y27632 (10 mM, Calbiochem), then treated with HMW-HA (50 mg/ml) in the continuing presence or absence of each reagent. For immunofluorescence analysis of RANKL, fixed cells were incubated overnight with the anti-RANKL antibody (1:100), then for 1 h at room temperature with FITC conjugated anti-goat IgG (Santa Cruz Biotechnology, Santa Cruz, CA, USA). To visualize stress fibers, cells were incubated with rhodamine phalloidin (Invitrogen) for 20 min at room temperature, then washed, mounted in mounting medium containing the nuclear stain, 4 0 6-diamidino-2-phenylindole dihydrochloride (DAPI; Vector Laboratories Inc., Burlingame, CA, USA), and visualized using a Fluorescence Microscope BZ-9000 (Keyence Corp., Osaka, Japan). Images were captured digitally in real time and processed using BZ-II imaging software (Keyence Corp.).
Quantitative real-time reverse transcription polymerase chain reaction (RT-PCR)
Total RNA was isolated from cells with TRIzol reagent (Invitrogen). Samples were reverse transcribed with q-Srcipt cDNA Supermix reagents (Quanta BioSciences, Gaithersburg, MD, USA) and amplified for 30 min at 42 C. For real-time RT-PCR, the PCR products were detected using FAST Ò SYBR Green Master Mix (Applied Biosystems, Foster City, CA, USA) using the following primer sequences: Gapdh forward; 5 0 -GACGGCCGCATCTTCTTGA-3 0 and reverse; 5 0 -CACACCGACCTTCACCATTTT-3 0 , and Rankl forward; 5 0 -GGCCAC AGCGCTTCTCA-3 0 and reverse; 5 0 -CCTCGCTGGGCCA-CATC-3 0 . Thermal cycling and fluorescence detection were performed using a StepOneÔ Real-Time System (Applied Biosystems). Real-time RT-PCR efficiency for each primer set was calculated according to the method of Rasmussen et al. 27 The fold increase in copy numbers of mRNA was calculated as the relative ratio of the Rankl gene to Gapdh, following the model of Pfaffl.
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Western blot analysis
Following incubation, total protein was extracted using Cell Lysis Buffer (Cell Signaling Technology) containing a protease inhibitor cocktail (Thermo Fisher Scientific, Waltham, MA, USA) and protein contents were measured using a DC protein assay kit (BioRad, Hercules, CA, USA). Twenty micrograms of total protein per sample was loaded and separated on a Mini-PROTEAN TGX 4e15% gradient SDS-PAGE gel (Bio-Rad), then transferred onto polyvinylidene difluoride membranes (Millipore Corp., Bedford, MA, USA). Nonspecific binding sites were blocked by immersing the membranes in 5% skim milk in PBS for 1 h at room temperature. Membranes were subjected to incubation overnight with diluted primary antibodies at 4 C, followed by horseradish peroxidase (HRP) conjugated secondary antibodies for 1 h at room temperature. After washing the membranes, chemiluminescence was produced using ECL reagent (Amersham Pharmacia Biotech, Uppsala, Sweden) and detected digitally with a GelDocÔ XR Plus System (Bio-Rad). Goat anti-RANKL and mouse anti-b-actin were used as the primary antibodies, while HRP-conjugated anti-goat IgG (Santa Cruz Biotechnology) and anti-mouse IgG (GE Healthcare, Little Chalfont, UK) were used as secondary antibodies.
RhoA activity
The amount of active RhoA was measured by using a pull-down assay with Rho Assay Reagent (Millipore Corp.), according to the manufacturer's instructions. Briefly, treated cells were washed twice in ice-cold PBS and lysed in lysis buffer (125 mM HEPES pH 7.5, 750 mM NaCl, 5% Igepal CA-630, 50 mM MgCl 2 , 5 mM EDTA, 10 % glycerol), then the lysates were clarified by centrifugation at 14,000 Â g for 5 min. Thereafter, the supernatant was incubated with Rhotekin-Rho binding domain beads for 45 min with gentle agitation at 4 C, after which the beads were washed 3 times with lysis buffer, followed by re-suspension in 40 ml of Laemmli reducing sample buffer. Precipitated GTP-bound and total RhoA proteins were then analyzed using western blotting analysis with an antiRhoA monoclonal antibody.
Osteoclast formation in co-culture system
Osteoclasts were detected by staining with tartrate-resistant acid phosphatase (TRAP) using an Acid Phosphatase Leukocyte Kit (SigmaeAldrich). In brief, ST2 cells ( (Riken Cell Bank, Ibaraki, Japan, 1 Â 10 3 cells/well) were overlaid for the co-culture system. After co-culturing for 7 days, adherent cells were fixed and stained for TRAP activity, with TRAP-positive multinucleated cells containing three or more nuclei counted under a microscope as osteoclast-like cells.
Statistics analysis
All statistics analyses were carried out using JMP Ò software, version 10.0.2 (SAS Institute Inc., Cary, NC, USA). Each of the data groups was tested by using ShapiroeWilk test and considered to follow a Gaussian distribution when the P-value was greater than 0.05. The Levene's test of homogeneity was used to determine the homogeneity of variance. All data were expressed as mean AE standard deviation and analyzed by one-way analysis if variance (ANOVA) and if significant, followed by the suitable posttest (Dunnett's or Tukey's post-test).
Results
HMW-HA down-regulates RANKL expression
We examined the effects of HMW-HA on RANKL expression in ST2 cells. The binding of HMW-HA (50 mg/ml) was monitored using an HABP probe and time-dependent HA binding could be visualized up to 3 h [ Fig. 1(A) ]. Primer sets for real-time RT-PCR amplification and quantification of mouse Rankl and Gapdh were designed, and the amplification efficiency of each set was determined, allowing for comparison of mRNA copy numbers between treated and control cultures, which were normalized to Gapdh. After 0.5 h of incubation with HMW-HA, there was a 26.4% decrease in Rankl mRNA copy number as compared to the untreated control cells [ Fig. 1(B) ]. This effect of HMW-HA was time-dependent, with maximum inhibition observed at the 1-h time point (96.3% inhibition). A concentration-dependent inhibition of Rankl by HMW-HA was also shown [ Fig. 1(C) ], which reached a maximum at a concentration of 50 mg/ml following 1 h of treatment (93% inhibition). As shown in [ Fig. 1(D) ], ST2 cell lysates from the control cultures expressed immunoreactive RANKL protein, while treatment with HMW-HA reduced RANKL protein expression in the ST2 cells for up to 48 h.
4-MU up-regulates RANKL expression
Next, we investigated whether the receptor-HA pathway has an influence on the expression of RANKL in ST2 cells using 4-MU. It has been reported that 4-MU inhibits HA synthesis and pericellular HA matrix formation in cultured cells. 29, 30 We found a time-dependent Changes in matrix interactions by HA affect RANKL accumulation ST2 cells at all examined culture times exhibited a background level of RANKL that was primarily localized on the cell surface [ Fig. 3(A) ]. No immunofluorescent staining was seen with the secondary antibody alone [ Fig. 3(B) ]. After 24 h of treatment with HMW-HA, RANKL protein accumulation was diminished [ Fig. 3(C) ]. On the other hand, after 24 h of treatment with 4-MU, RANKL levels were substantially enhanced [ Fig. 3(D) ]. 
Discussion
Bone resorption has been reported to be increased in women with progressive knee OA as compared to those with nonprogressive disease 34 . Furthermore, peripheral blood mononuclear cells from patients with OA have been shown to exhibit enhanced capacity to generate osteoclasts and higher levels of bone resorption in vitro 35 , while inhibition of osteoclastic activity by bisphosphonate was found to prevent bone and cartilage resorption in a rat degenerative joint disease model 36 . Therefore, there is great interest in identifying the effects of HMW-HA on osteoclastogenesis as a target for developing therapeutic agents to prevent joint destruction in OA.
In the present study, we used a homogeneous clonal population of mouse bone marrow stromal ST2 cells to elucidate the effects of HMW-HA on induction of osteoclast differentiation. This cell line is known to highly express RANKL in the presence of 1,25(OH) 2 D 3 and RANKL-expressing cells support the differentiation of splenic cells into osteoclasts 37 . The main advantage of the present system is that it does not contain any pre-osteoclast cells, which may also be targets of HMW-HA activities.
As shown in Figs. 1 and 3 , RANKL mRNA and protein were decreased by addition of HMW-HA, indicating that it has protective effects against osteoclastogenesis. Chang et al. reported that HMW-HA (1,300 kDa) decreased osteoclast formation by bone marrowderived macrophages and human peripheral blood monocytic cells, but not by RAW 264.7 cells 25 . In the study, they discussed that the difference in effects of HMM-HA between RAW 264.7 cells and primary osteoclast precursors may be ascribed to the independence of RAW 264.7 cells on macrophage colony stimulating factor (M-CSF) for proliferation and osteoclastic differentiation. Furthermore, our results would suggest that suppression of osteoclastogenesis by HMW-HA is also dependent on down-regulation of RANKL expression in osteoblasts/stromal cells. In contrast to those findings, Cao et al. reported that HMW-HA stimulated RANKL expression in bone marrow stromal cells 38 . We have no ready explanation for these contrasting results, though it is possible that they reflect differences in the cell species tested or variations in culture conditions, including the presence or absence of serum. The modified coumarin, 4-MU has been reported to specifically inhibit HA synthesis and pericellular HA matrix formation in cultured mammalian cells 29, 30 . Several studies have reported the various biological effects of 4-MU on inflammatory response in arthritis 39 , tumourigenicity 40 , and nerve injury 41 . As shown in Figs. 2 and 3 , we found that 4-MU up-regulated RANKL expression, and our observations suggest that inhibition of HA synthesis and loss of cellematrix interaction enhance osteoclast differentiation and bone resorption. In addition, the effect of 4-MU on proliferation of ST2 cells was examined using a WST-1 assay, though no effect on cell growth up to 48 h was seen.
Another important finding of our study is that the HA receptor CD44 is required for down-regulation of RANKL mediated by HMW-HA. CD44 is one of the major HA binding proteins and expressed in several types of cells, including osteoblasts 42 , while binding of HA to CD44 is known to be involved in onset of a variety of biological activities. The monoclonal rat anti-CD44 antibody recognizes a determinant of the HA binding region common to CD44 and its principal variant isoforms 43 and that antibody is routinely used in HA-related blocking experiments. As shown in [Fig. 4(A) ], pre-treatment with that CD44 functionblocking monoclonal antibody resulted in significantly reduced accumulation of exogenous HMW-HA in ST2 cells. We also found that this antibody remarkably inhibited the effect of HMW-HA on down-regulation of RANKL in ST2 cells [ Fig. 4 (B) and (C)]. On the basis of these findings, we speculate that expression of CD44 in ST2 cells, which have the same lineage as osteoblasts, leads to regulation of osteoclast formation and activation mediated by HMW-HA.
Rho GTPases (RhoA, Rac1, Cdc42) are members of the Rho subclass of the Ras superfamily 44 , and have a cycle between active GTP-bound states and inactivate GDP-bound states in response to external stimuli. In their active form, they regulate key signaling pathways and control a variety of cellular activities, including gene transcription, cytoskeleton reorganization, cell growth, migration, and oncogenesis 45 . Previous studies have also found that HA-CD44 binding induces RhoA signaling in head and neck tumor cells 46 . In the present study, addition of HMW-HA led to a significant increase in the level of active GTP-bound RhoA [ Fig. 5(A) ], while pre-treatment with the CD44 function-blocking monoclonal antibody remarkably inhibited HMW-HA-induced RhoA activation in ST2 cells [ Fig. 5(B) ]. These results demonstrated that HA-CD44 interaction also induces RhoA signaling in osteoblasts/stromal cells. Recent findings indicate that the RhoA signaling pathway has important roles in bone remodeling. For example, in osteoblast survival 31 , the integrity of the actin cytoskeleton 32 , as well as migration and differentiation 33 are regulated by RhoA signaling.
Simvastatin has been reported to reduce the synthesis of mevalonate by inhibiting hydroxymethylglutaryl (HMG)-CoA reductase, finally leading to blockade of Rho GTPases by the effector proteins ROCK 47 . On the other hand, Y-27632, a pyridine derivative, was discovered to particularly disrupt ROCK signaling 48 and has been widely investigated in various studies. We found that blockage the RhoA/ROCK pathway by either simvastatin or Y-27632 prevented a decrease in RANKL expression caused by exposure to HMW-HA [ Fig. 6 ]. These findings are consistent with a previous study, in which the expression of constitutively active RhoA in osteoblastic cells was shown to impair their ability to induce osteoclastogenesis via suppression of RANKL mRNA in response to parathyroid hormone or calcitol. 49 As a catabolic effect on bone, 1a,25(OH) 2 D 3 promotes osteoclastogenesis by up-regulating the expression of RANKL. In the present study, administration of HMW-HA decreased RANKL expression induced by 1a,25(OH) 2 D 3 [ Fig. 7(A) ], while simvastatin and Y-27632 recovered that decreased expression in cells treated with HMW-HA [ Fig. 7(B) ]. HMW-HA also prevented osteoclast differentiation of co-cultured precursors supported by stromal cells expressing RANKL [ Fig. 7(C) and (D) ]. These results suggest that activation of RhoA/Rho kinase signaling by HMW-HA inhibits RANKL in bone marrow stromal cells, thereby inhibiting osteoclastogenesis. Furthermore, 1a,25(OH) 2 D 3 was reported to suppress the gene expression of osteoprotegerin (OPG), which acts as a decoy receptor for RANKL and prevents RANKeRANKL interaction, and thus osteoclastogenesis 50 . In our study, HMW-HA recovered upregulation of RANKL expression, while the down-regulation of OPG was mediated by 1a,25(OH) 2 D 3 (data not shown). Bone resorption is a multistep process initiated by the proliferation of immature osteoclast precursors, which is followed by the commitment of those cells to the osteoclast phenotype and degradation of the organic and inorganic phases of bone by mature resorptive cells. We previously reported that TRAP positive multinucleated cells differentiated from RAW 264.7 cells by RANKL are capable of bone resorption using calcium phosphate substrate coated slides 26 . From those results, the molecular mechanism for the effect of HMW-HA on OPG expression and on osteoclast function are currently under investigation in our laboratory. HA is known to be associated with several cell surface molecules, such as CD44, receptor for hyaluronan-mediated motility (RHAMM), toll-like receptor-4 (TLR4), and intercellular adhesion molecule (ICAM-1). It has also been reported that RHAMM, TLR4, and ICAM-1 are expressed in osteoblast stromal lineage cells. Further study is needed to examine the correlations between HMW-HA and other receptors regarding inhibition of osteoclast formation, as well as signal transduction during osteoclastogenesis.
In conclusion, the present findings showed that HMW-HA inhibits the transcription of RANKL in stromal cells by activating the RhoA/Rho kinase pathways. CD44-mediated signaling supports this activation and is likely critical for certain cell types, such as stromal cells. Furthermore, our results suggest that stromal cells have a capacity to sense changes in cell surface HA-CD44 interactions, resulting in regulation of bone metabolism. Whether analogous effect of HMW-HA on osteoclast occurs in human cells or in vivo animal model remains to be determined. Nonetheless, we consider that these results provide a basis to understand why HMW-HA is effective when used as treatment for OA.
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